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Abstract
Background: Lung transplantation is a well-established treatment for end-stage non-cystic fibrosis bronchiectasis
(BR), though information regarding outcomes of transplantation remains limited. Our results of lung transplantation
for Br are reported here.
Methods: A retrospective review of case notes and transplantation databases was conducted for patients that had
underwent lung transplantation for bronchiectasis at the Freeman Hospital between 1990 and 2013.
Results: Fourty two BR patients underwent lung transplantation, the majority (39) having bilateral sequential lung
transplantation. Mean age at transplantation was 47.1 years. Pre-transplantation osteoporosis was a significant non-
pulmonary morbidity (48%). Polymicrobial infection was common, with Pseudomonas aeruginosa infection
frequently but not universally observed (67%). Forced expiratory volume in 1 second (% predicted) improved from
a pre-transplantation mean of 0.71 L (22% predicted) to 2.56 L (79 % predicted) at 1-year post-transplantation. Our
survival results were 74% at 1 year, 64% at 3 years, 61% at 5 years and 48% at 10 years. Sepsis was a common cause
of early post-transplantation deaths.
Conclusions: Lung transplantation for end-stage BR is a useful therapeutic option, with good survival and lung
function outcomes. Survival values were similar to other bilateral lung transplants at our centre. Pre-transplantation
Pseudomonas infection is common.
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Background
Bronchiectasis is an abnormal dilation of the bronchi
and bronchioles that results in chronic cough, sputum
production and recurrent infections. Bronchiectasis can
lead to progressive loss of lung function, resulting in
chronic morbidity and premature mortality [1]. Bronchi-
ectasis not due to cystic fibrosis (often referred to as
non-cystic fibrosis bronchiectasis; thereafter BR) has
diverse causes, though post-infectious and idiopathic
bronchiectasis are the most common [2, 3].
BR has been identified as a cause of increasing mor-
bidity and mortality in the U.S. and Europe [4–6]. As
Bronchiectasis is increasingly encountered (or recognised)
there is a greater need to understand the benefits and risks
of lung transplantation for this indication. Lung trans-
plantation is an intensive therapeutic intervention that
can be performed for the treatment of end-stage BR [7, 8].
However, the recent guidelines from the British Thoracic
Society (BTS) specifically note scarce data on the results
of lung transplantation for bronchiectasis [2]. This know-
ledge gap results in uncertainty for clinicians in managing
patients with more severe bronchiectasis.
A number of studies have assessed the association be-
tween pathogenic microorganisms and prognosis in
adult BR. Persistent Pseudomonas aeruginosa infection is
seen in approximately 30-40% of BR patients and it is
linked with a poorer quality of life and increased mortal-
ity [9, 10]. Furthermore, it predicts a more severe disease
phenotype with increased hospitalisation rates and is as-
sociated with poorer lung function and accelerated
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functional decline in BR patients [9–12]. In some set-
tings, Pseudomonas infection post-transplantation has
been linked with increased rates of allograft dysfunction/
obliterative bronchiolitis [13]. In contrast, information
regarding the prognostic effects of pre-transplantation
Pseudomonas status on both early and long-term out-
comes of lung transplantation for BR remains limited.
In view of the above, we aimed to assess the survival
outcomes of patients transplanted for BR at our centre.
Additionally, we aimed to investigate a range of pre-
transplant factors including pre-transplantation micro-
biology and their relationship to post-transplantation
outcomes.
Methods
Our primary outcome of interest was post-transplant
survival in those transplanted for BR. Other aims were
to describe the demographic profiles of patients trans-
planted and the post-transplant outcomes in patients
with BR as compared to other lung transplant
indications
Case finding and definitions
A retrospective analysis of the pulmonary transplant-
ation databases and case notes was performed for all BR
patients who underwent pulmonary transplantation at
our institution from 1990 to 2013. All adult recipients
with bronchiectasis as a primary diagnosis were assessed
and their case notes and microbiological results
reviewed. In general, the exclusion of cystic fibrosis was
through genetic testing by UK Health service genetic la-
boratories and/or sweat tests in line with more recent
guidelines. Immunological work up included assessment
of serum immunoglobulins although additional tests
were performed upon consultation with immunologists
if clinical suspicion of immunodeficiency was made.[2]
As a control group we included all lung transplants for
any other indication across the same time cohort. Data
where available were extracted to define the Bronchiec-
tasis severity index scores [4], the FACED scores [14]
and the eFACED scores [15].
Peri-transplantation management
Induction therapy changed over the time cohort but
has included intravenous methylprednisolone and in
earlier patients included anti-thymocyte globulin [16]. A
3-day induction protocol with intravenous methylpred-
nisone (2 mg/kg) was used in the majority of patients.
Post-transplantation immunosuppression comprised of
cyclosporine, prednisolone and azathioprine for all pa-
tients [16]. Prophylactic antibiotics were given to the re-
cipient in accordance with the most recent sensitivities
derived from sputum cultures as per our CF protocol
[16]. Aztreonam (2 g) 8 hourly for 2-7 days was used if
the isolate was multiply resistant. Multiple antibiotic
synergy testing has been incorporated since 2001 into
our microbiological work up using previously described
methods [17, 18].
Operative interventions
Bilateral single sequential lung transplantations (BSLTx)
were performed via clamshell incisions as per our CF
lung transplant protocol [16]. The donor bronchial
stump was kept as short as possible to avoid ischaemic
injury. Cardiopulmonary bypass was used in all cases
with aprotinin used as standard. Heart-lung transplant-
ation was performed via sternotomy with tracheal anas-
tomosis and bicaval anastomosis.
Surveillance associated complications
Surveillance transbronchial biopsies and bronchoalveolar
lavage (BAL) were routinely performed at 1 week, 1
month, 3 months, 6 months and one year post-trans-
plant and at times of deterioration [16]. Acute vascu-
lar rejection grade A2 or greater were recorded.
Major complications of transbronchial biopsy were re-
corded as present if there was requirement for chest
drain insertion, biopsy associated bleeding with re-
quirement for invasive ventilation or death following
a procedure [16].
Obliterative bronchiolitis
Pulmonary function tests were performed according to ac-
cepted guidelines. The data were collected prior to the use
of chronic allograft dysfunction in clinical practice [19] so
Bronchiolitis obliterans syndrome terminology was used.
We used “Freedom from BOS” as previously [20] to define
patients who failed to demonstrate a fall in FEV1 to the
threshold used for BOS 1 or higher. The best consecutive
FEV1 attained as directed by the guidelines was used to
set thresholds for BOS 1 (FEV1 66-80% of best recorded
post-transplantation FEV1) BOS 2 (FEV1 51-65%) and
BOS 3 (FEV1 <50%). BOS 0-p (potential for BOS develop-
ment) was also recorded.
Survival analysis and causes of death recording
Survival data are routinely collected as part of the national
transplant surveillance programme. StatView software V.
4.5 was used to conduct actuarial survival analysis within
our cohort. Causes of post-transplantation mortality were
recorded from patient notes where available. Sepsis related
deaths were recorded where a pathogen was identified
clinically as causal to the recipient’s death or where a clin-
ical diagnosis of infection was made and alternate diagno-
ses were excluded.
Microbiology
Peri-transplantation microbiology from sputum and/or
BAL of the recipient lung on the day of transplantation
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was recorded from patient notes and the microbiology
database. In most cases sputum was collected with infre-
quent need for BAL at transplant. Pre-transplantation
sputum microbiology results e.g. from referring centres
or at our transplant assessment visits were also recorded
from patient notes. The presence/absence of bacterial
infection was based on qualitative microbial culture. No
quantitative cultures were undertaken. Pulsed field gel
electrophoresis assessment of microbiological clonality
was not routinely conducted. Post-transplantation BAL
data from routine surveillance BAL undertaken at 1 year
was cross-checked between the computerised pathology
reporting system and from paper records.
Systemic disease
Pre-transplantation cardiac dysfunction, body mass
index (BMI) and osteoporosis rates from Dual-energy
X-ray absorptiometry (DEXA) scans were captured.
Post-transplantation renal function was determined by
serial serum creatinine levels that were recorded pre--
transplantation and at 1 year, 5 years and 10 years post-
transplantation.
Results
The total number of lung transplantation procedures
performed for all indications at data capture (1990-2013)
was 752, with 42 lung transplantations performed for BR
(6% of the total lung transplant population). There were
39 patients that underwent BSLTx from cadaveric do-
nors, one patient had single lung transplantation (SLTx)
and two patients had heart-lung transplantation. Lung
transplantation commenced at this institution in 1987
with the first transplantation for BR performed in 1990.
The assessment protocol has evolved in this time period
and hence full datasets are not available for all
parameters.
There were 25 patients transplanted for BR be-
tween 1990 and 2000 from a total of 260 lung trans-
plants performed (9.6%). Significantly fewer were
transplanted between 2001 and 2011; 17 from a total
of 429 (4.0%; Chi-square test, p<0.001). Thus, lung
transplantation for BR was less frequent in the sec-
ond 10-year time cohort compared to the first 10
years of transplantation. All recipients were adults
(age >17 years), with a mean age at transplantation
of 47.1 years (range; 22.6-62 years). There were 13
female patients (31%) and 29 male patients (69%)
transplanted. For the control cohort (all sequential
single lung transplants performed for any other indi-
cation) the mean age was 42 years with 42% female
and 58% male (the majority of these other indica-
tions were cystic fibrosis and COPD without
bronchiectasis).
Bronchiectasis aetiology
Bronchiectasis aetiology was categorised in 29 of 42
patients, with post-infectious (9 patients), idiopathic (6
patients) and COPD-associated (5 patients) accounting
for the majority of cases (31%, 21% and 17% of cases,
respectively).
Bronchiectasis associated with Kartagener’s syndrome
was noted in 14% of cases (4 patients) and Young’s syn-
drome in 10% of cases (3 patients). Neonatal ventilatory
trauma and X-linked agammaglobulinaemia led to sec-
ondary bronchiectasis in single cases. In the remaining
cases the presumptive aetiologies were idiopathic or post
infectious but insufficient details were available to con-
clusively exclude other aetiologies.
Bronchiectasis severity scores
Full data sets were not available in all transplant recipi-
ents. We were able to calculate the BSI, FACED and
eFACED scores in 34 patients. According to the BSI, 33
had severe bronchiectasis (score 9 or greater) and one
had moderate severity (BSI score 7). In contrast whilst
18 were deemed to have severe bronchiectasis 16 were
deemed to have moderate bronchiectasis according to
FACED. Using eFACED scores, 28 were deemed to have




The mean pre-transplantation FEV1 at lung transplant
assessment was 0.71l ± 0.27 (22 % predicted) (n = 37).
From 36 patients where full data was available, 32 were
in respiratory failure (89 %) and on long-term oxygen
therapy. Of these, one patient was on long-term non-
invasive ventilation (NIV).
Pre-transplantation arterial blood gas values taken at
assessment were available for 35 patients. The mean
PO2 was 8.3 ± 2.8kPa and mean pCO2 was 6.9 ± 1.2kPa
(30/35 patients on oxygen therapy). Six minute walk test
mean distance walked was 280.8 metres (range; 60-640
metres), with lowest arterial oxygen saturation recorded
at a mean of 75.4% (range; 49-91%) (n = 36).
Data regarding other co-morbidities were available for
31 of 42 patients. Of these, we noted 12 patients (39%)
with a co-existent diagnosis of asthma pre-
transplantation.There were 10 patients (32%) with
COPD. Five were felt to have COPD as an aetiology and
five patients had another diagnosis felt to be the primary
cause of the bronchiectasis but also had COPD listed as
a comorbidity. A history of previous pneumothorax was
reported by 4 patients (13%). We noted 3 patients (10%)
with echocardiographic evidence of pulmonary hyper-
tension and 2 patients (6%) with clinical features of aller-
gic bronchopulmonary aspergillosis.
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Non-Pulmonary disease
Osteoporosis was a significant non-pulmonary pre-
transplantation morbidity affecting 14 patients (48%) (n
= 29). 3 patients had documented pre-transplantation
diabetes (10%, n=31). Pre-transplantation echocardio-
gram results were available for 33 patients. Of these pa-
tients, 18 (55%) had an abnormal result, with some
patients having multiple abnormalities. Right ventricu-
lar dilation was noted in 13 cases, right ventricular
atrophy in 4 cases, left ventricular dilatation noted in
2 cases and pulmonary hypertension noted in 1 case.
Pre-transplantation ischaemic heart disease affected 2
patients (6%) and Wolff-Parkinson-White syndrome
affected one patient. At assessment the pre-
transplantation mean BMI was 25.4 kg/m2 (± 4.8)
(range; 16-31.9 kg/m2) (n = 25).
Survival and causes of death
The survival figures for the whole cohort were 74% sur-
vival at 1 year, 64% at 3 years, 61% at 5 years and 48% at
10 years (Fig. 1).,The calculated 50% survival was at 9.3
years. We compared our Kaplan-Meier survival rates for
the BR cohort with that of BSLTx for all other trans-
plantation indications at our centre (Fig. 1). There was
no significant difference in survival between the BR and
non-BR transplantation cohorts (log rank testing;
Mantel-Cox, p = 0.23).
At data capture, 14 of 42 BR lung transplant recipients
were alive (33%). Data allowing determination of cause
of death was available in 13 cases (Table 1). Death
caused by sepsis was noted in 5 cases (staphylococcal in-
fection was identified as a cause of death in two cases
and cytomegalovirus in one case). In the remaining two
cases, a sepsis syndrome was identified although no
specific pathogen was isolated. Therefore 38% of all
recorded BR transplantation recipient deaths were due
to sepsis where data were available. Of the sepsis-related
deaths, 3 occurred early post-transplantation. None of
these occurred in patients with known immunodefi-
ciency related bronchiectasis. Multi-organ failure occur-
ring within the first month following transplantation was
the cause of death in 2 cases. Later causes of death in-
cluded respiratory failure or obliterative bronchiolitis,
which was recorded in 4 cases. Other identified causes
of death include malignancy (n = 1, post transplantation
lymphoproliferative disease) and cerebrovascular acci-
dent (n = 1).
Pulmonary function post-transplantation
Mean pre-transplantation FEV1 was 0.71l ± 0.27 (22%
predicted) (n = 37), which improved to 2.56l ± 1.02 (79
% predicted; n=31) at 1 year post-transplantation. The
mean FEV1 at 5 years post-transplantation was 2.3l ±
0.95 (74 % predicted) (n = 18) and 2.36l ± 0.72 (78%
predicted) (n = 9) at 10 years post-transplantation (p
<0.001 at each time point compared with pre-
transplantation values; paired t-test).
The prevalence of severe airflow limitation as BOS 3
was 18% at 1 year and 25% at 5 years. Where data were
available at 10 years post-transplantation, no patients
were at stage BOS 3 (n=9).
Renal disease
Mean serum creatinine for patients at pre-transplantation
assessment was 83.2 mg/dl (± 17.4) (range; 53-118 mg/dl)
(n = 39). By 1-year post-transplantation, creatinine levels
worsened for all patients, rising to a mean of 166.8 mg/dl
(± 60.2) (range 73-281 mg/dl) (n = 29) (p <0.001; paired t-
test). Of those patients still alive at data capture, no
patients had however required haemodialysis or had
Fig. 1 Actuarial survival of patients with non-CF bronchiectasis (BR) at the Freeman Hospital Lung Transplant Programme (n=42) compared with
all other bilateral sequential single lung transplants (BSLTx) performed at our centre (n=409). No significant difference in survival was found
between the cohorts (log-rank testing; Mantel-Cox, p = 0.23).
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undergone renal transplantation following lung trans-
plantation (n = 14).
Surveillance biopsies
Acute vascular rejection (grade A2 or greater, as defined
by the International Society for Heart Lung Transplant-
ation (ISHLT)) [21] was noted in 2 patients from avail-
able transbronchial biopsy results at 3 months and 6
months post-transplantation (n = 14). Of all patients
alive at data capture, none had experienced significant
morbidity (e.g. invasive mechanical ventilation or blood
transfusion) or mortality following standard transbron-
chial biopsy procedures at the unit.
Microbiology
Peri-transplantation microbiological cultures, including
those at or before transplantation assessment, immedi-
ately pre-operatively and at 1 year post-transplantation
were carried out. Polymicrobial infections in individual
recipients were common (Fig. 2). We noted 67% of
patients (where data were available, n = 36) had docu-
mented history of infection with P. aeruginosa before
transplantation assessment. At transplant assessment,
62% of patients were infected with P. aeruginosa (n =
34) and at time of transplantation 45% of patients were
infected with P. aeruginosa (n = 37). None of the pa-
tients in this cohort had infection with pan-resistant P.
aeruginosa, however 45% of patients were recorded as
having previous infection with multi-resistant P. aerugi-
nosa (n = 20).
Other organisms commonly isolated pre-transplantation
include a mixture of probable commensals and pathogens:
Candida was noted in 44% of patients, Aspergillus spp. in
30%, Haemophilus influenzae infection in 28%,
Streptococcus pneumoniae in 19%, Stenotrophomonas
spp. infection in 17%, methicillin resistant Staphylo-
coccus aureus (MRSA) infection in 14%, Moraxella
catarrhalis in 14% and Alcaligenes spp. infection in
3% (n = 36).
Prior to transplantation 24 patients (69%) of 35 patients
with available data, were taking nebulised antibiotics. Only
4 patients were receiving azithromycin pre-transplantation,
Fig. 2 Microbial infections prior to transplantation. Percentage of the cohort (where data were available) infected with each pathogen is noted.
The majority of patients had more than one pathogen isolated from the same individual’s sputa in the year before transplantation. MRSA,
methicillin resistant S aureus.
Table 1 Causes of death in non-CF bronchiectasis recipients
transplanted at the Freeman Hospital





Respiratory failure 2 (15)
Obliterative bronchiolitis 2 (15)
Multi-organ failure 2 (15)
Malignancy 1 (8)
Cerebrovascular accident 1 (8)
Total No of deaths 13 (100)
Transplant Programme. Causes of death in recipients were recorded from case
notes. Data are expressed as percentage of deaths observed in this cohort
where data detailing cause of death were available. Data was available for 13
patients, however 28 patients from the cohort were deceased. Percentages
have been rounded up or down to the first decimal place
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perhaps reflecting the more recent widespread use of
macrolides in inflammatory lung disease.
Post-transplantation lavage
Microbiology results for BAL specimens collected at 1
year post-transplantation were retrieved for 29 patients
of the 31 recipients alive at 1 year. Most did not grow
respiratory pathogens in their BAL (18 patients, 62%).
The most commonly isolated pathogen was P. aerugi-
nosa in 6 patients (21%), all of whom had persistent P.
aeruginosa infection prior to transplantation. Other or-
ganisms isolated included Candida species (3 patients;
10%), Staphylococcus aureus (2 patients; 7%), Aspergillus
fumigatus (1 patient; 3%) and Paecilomyces lilacinus (1
patient).
Discussion
Despite exciting new therapeutic pipelines in BR, a
rising mortality rate and increasing hospitalisation
rates for BR suggests there are significant unmet medical
needs [6, 9]. Lung transplantation is one option for man-
aging severe end stage BR. Lung transplantation for BR ac-
counts for 6% of all lung transplantations performed at
our centre, a distribution similar to that of the Inter-
national Society for Heart Lung Transplantation (ISHLT)
registry [21, 22]. We noted excellent post-transplant out-
comes with greater than 50% survival at 5 years. Our out-
comes were comparable to lung transplant outcomes for
other indications at our centre. Our approach has pre-
dominantly been with BSLTx, which has been argued as
the procedure of choice for this group of patients [21, 22].
Notably BR has been calculated to have a better cost
effectiveness outcome following lung transplantation as
compared to COPD, the commonest indication for lung
transplantation [23]. The combined UK transplant experi-
ence also suggested that BR has one of the best post-
transplant outcomes [24].
In view of this, the low rates of lung transplantation
for BR need to be considered. They may be due to a
number of factors including concerns about the risk
benefit ratio of lung transplantation in BR. The preva-
lence of BR peaks in older patients who may be per-
ceived beyond the optimal window for lung
transplantation. Furthermore the lack of a validated
prognostic scoring systems for BR in contrast to those
for COPD may prevent timely referral for lung trans-
plantation [25]. The role of either of the recently
published indices, Bronchiectasis severity index (BSI) [4]
or FACED score [14] in guiding transplant referrals
remains to be defined. We noted that the majority of
patients were classified as severe bronchiectasis using
BSI but not with FACED. Further studies are needed to
define the role of these scores in helping prompt referral
for transplant assessment. These latter scores
underrepresent those with severe disease until the age is
beyond 70 years due to the weighting of the scores.
As highlighted in recent BR guidelines very few studies
have examined lung transplantation in detail. The sur-
vival in our series was similar to the survival figures pre-
viously reported by our institution for CF patients [16].
The most recent case series of 34 patients from
Germany reported good outcomes for bronchiectasis
with one-year Kaplan-Meier survival for patients with
bronchiectasis being 85% and 5-year survival being 73%.
These outcomes were comparable to the overall lung
transplant cohort. Notably however the mean age group
was much younger at 40 years. In those with pre-
transplant Pseudomonas infection poorer outcomes and
higher rates of BOS were reported from the Hannover
group [26]. The UK wide experience spanning 5 centres
with 123 BR patients listed for transplantation was noted
in a study of all lung transplant indications published in
2009 [24]. Unfortunately, little in depth data beyond sur-
vival in BR were available but the study demonstrated
only 54 BR patients listed survived on the waiting list to
transplantation (48%). Of those transplanted the median
waiting time on the list was nearly 1 year with a median
post-transplantation survival of 3000 days. Notably the
BR post-transplantation survival was the best of 5 major
indications for lung transplantations. Despite this appar-
ently good outcome it seems unlikely that the BR cohort
were less sick than the other indications studied; along
with interstitial lung disease, BR had the highest “on-list”
pre-transplantation mortality rates (59/123 died on the
waiting list). This correlates well with our observed high
rates of respiratory failure and secondary pulmonary
hypertension in our cohort.
The ISHLT registry data show that the major causes
of mortality in the first year following lung trans-
plantation for any indication are graft failure and in-
fection. We noted a large range of pathogens with
potential to complicate the early postoperative period.
Our immediate pre-transplantation rate of Pseudo-
monas infection was 45%, which is broadly similar to
a prior Spanish series of 17 patients where 64% of pa-
tients had Pseudomonas infection pre-transplantation
[27]. These contrast with our experience in CF, where
the majority of patients had Pseudomonas pre-
transplantation [16].
BR transplant recipients could be predicted to suffer
high rates of infection or, in the event of over-
cautious immunosuppression, high rates of acute
rejection. Firstly we observed an early septic death
rate of 7%, which appears similar to that observed
elsewhere for other non-septic lung transplantation
[16]. Whilst there were high rates of multi-resistance
in those with Pseudomonas infection, none were pan-
resistant. Furthermore, the septic deaths were
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unrelated to Pseudomonas infection per se. The prior
literature denotes that Pseudomonas infection is seen
in those with more severe bronchiectasis, which has
led other authors to conclude that it is a marker of
more severe lung disease. It is plausible that a non-
significant trend towards more deaths in the Pseudo-
monas group herein reflects more severe disease.
Alternatively, as suggested by Rademacher and col-
leagues in the Hannover series, Pseudomonas may be
driving poorer outcomes [26].
The previously noted UK wide BR transplant data
set of 54 patients is likely to include many of the 37
BR patients transplanted at Papworth Hospital, re-
ported in a case series in 2005 [28]. In this cohort,
32 were defined as “bronchiectasis alone” and the
remaining 5 had an antibody deficiency that required
immunoglobulin replacement therapy. In this latter
case series the observed actuarial survival was similar
in the 2 groups (81% at 12 months in the bronchiec-
tasis group and 80% in the antibody deficiency
group). The post-operative complication rates were
acceptable with infection episodes per 100 patient-
days for bronchiectasis alone being 0.90 vs. 0.53 and
rejection episodes per 100 patient-days being 0.59 vs.
0.24. Whilst we did not quantify rejection rates in
this manner, our rates of symptomatic or surveillance
rejection were not detected.
Whilst this is the largest single centre study of lung
transplantation in bronchiectasis to date limitations of
our study should be acknowledged. These include miss-
ing data points: whilst there were 28 deaths we could
only report data on 13 of these cases reflecting that
many of the deaths occurred late transplant and oc-
curred at the referring centre and not transplant centre.
The newer definition of chronic lung allograft dysfunc-
tion (CLAD) [19] was not used in our study awaiting
ISHLT guidelines on the implementation of CLAD. The
study is limited by the sample size that are inherent in
the single centre retrospective design. Furthermore there
have been changes in both our peri transplant protocols
reflecting novel immunosuppressants and anti-viral
agents used over the study period. Additionally the ma-
jority of the transplants performed are sequential single
lung transplants so we cannot define the differences
between heart-lung transplantation and our preferred
operative type. Larger multicentre studies, with multi-
variate analyses, that define pre-transplant characteris-
tics that are associated with increased risks of early
deaths would be helpful. Nevertheless our study high-
lights important findings that have not been reported be-
fore. Important areas to be considered for future studies
will be an assessment of rejection rates and frequency of
and prognostic implications of clonal Pseudomonas
strains [29].
Conclusions
Transplantation for BR has excellent outcomes yet poor
on-list survival [24]. In our experience the numbers of
transplants for this indication may be declining for rea-
sons unknown. Physicians should consider transplan-
tation as an option in those with severe bronchiectasis.
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